Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 7/20 | 0.49 |
| ▸ | GRB2 | P62993 | 1/20 | 0.43 |
| ▸ | MDM2 | Q00987 | 4/20 | 0.42 |
| ▸ | CTSD | P07339 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27172564 | 1.00 | PTPN1 (0.49) | PTPN1GRB2MDM2CTSDCTSK | |
| SCHEMBL27204705 | 1.00 | PTPN1 (0.49) | PTPN1GRB2MDM2CTSDCTSK | |
| SCHEMBL30069018 | 0.91 | PTPN1 (0.48) | PTPN1GRB2MDM2CTSKCTSB | |
| SCHEMBL7391230 | 0.88 | PTPN1 (0.46) | PTPN1CTSDCTSKCTSLCTSB | |
| SCHEMBL7391232 | 0.88 | PTPN1 (0.46) | PTPN1CTSDCTSKCTSLCTSB | |
| SCHEMBL30018616 | 0.86 | CASP3 (0.49) | MDM2 | |
| SCHEMBL30516251 | 0.85 | PTPN1 (0.54) | PTPN1MDM2CTSKCTSL | |
| SCHEMBL30516241 | 0.85 | PTPN1 (0.54) | PTPN1MDM2CTSKCTSL | |
| SCHEMBL30516235 | 0.85 | PTPN1 (0.54) | PTPN1MDM2CTSKCTSL | |
| SCHEMBL30516240 | 0.85 | PTPN1 (0.54) | PTPN1MDM2CTSKCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240294569-A1 | MODULATORS OF SORTILIN ACTIVITY | VESPER BIO APS (DK) | 2024-09-05 | — | — | US | disclosed |
| EP-4337674-A2 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2024-03-20 | — | — | EP | disclosed |
| WO-2022238565-A2 | COMPOUNDS | INSUSENSE ApS (DK) | 2022-11-17 | — | — | WO | disclosed |
| EP-4089102-A1 | MODULATORS OF SORTILIN ACTIVITY | Insusense ApS (DK) | 2022-11-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240294569-A1 | MODULATORS OF SORTILIN ACTIVITY | SORT1, SCARB1, NPC1 | PTPN1 1269/4885GRB2 2333/4885MDM2 4765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.